Zynerba Press Releases

12 Jul 18 Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

9 Jul 18 Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

5 Jul 18 Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

31 May 18 Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

8 May 18 Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

25 Apr 18 Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

23 Apr 18 Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

16 Apr 18 Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

10 Apr 18 Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)

26 Mar 18 Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model